Stock Track | HUTCHMED Soars as UK Approves Cancer Drug Fruquintinib

Stock Track

Sep 20, 2024

Shares of HUTCHMED (HCM), a leading biopharmaceutical company focused on oncology and immunology drugs, soared 7.58% on Thursday after the UK's healthcare regulator granted approval for its drug Fruquintinib to treat metastatic colorectal cancer in adult patients.

The Medicines and Healthcare products Regulatory Agency (MHRA) approval marks a significant milestone for HUTCHMED, allowing the company to market Fruquintinib in the UK for colorectal cancer treatment. Fruquintinib is a highly selective and potent oral inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3.

The regulatory greenlight bolsters HUTCHMED's oncology portfolio and is expected to drive revenue growth for the company. Analysts view the approval as a positive development, highlighting the drug's potential in addressing a significant unmet medical need in the treatment of metastatic colorectal cancer.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1151558670"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1151558670\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1151558670?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-20 20:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1151558670","market":"us","top_or_hot":-1,"title":"Stock Track | HUTCHMED Soars as UK Approves Cancer Drug Fruquintinib","media":"Stock Track","content":"<p>Shares of HUTCHMED (HCM), a leading biopharmaceutical company focused on oncology and immunology drugs, soared 7.58% on Thursday after the UK's healthcare regulator granted approval for its drug Fruquintinib to treat metastatic colorectal cancer in adult patients.</p>\n\n<p>The Medicines and Healthcare products Regulatory Agency (MHRA) approval marks a significant milestone for HUTCHMED, allowing the company to market Fruquintinib in the UK for colorectal cancer treatment. Fruquintinib is a highly selective and potent oral inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3.</p>\n\n<p>The regulatory greenlight bolsters HUTCHMED's oncology portfolio and is expected to drive revenue growth for the company. Analysts view the approval as a positive development, highlighting the drug's potential in addressing a significant unmet medical need in the treatment of metastatic colorectal cancer.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | HUTCHMED Soars as UK Approves Cancer Drug Fruquintinib</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | HUTCHMED Soars as UK Approves Cancer Drug Fruquintinib\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2024-09-20 20:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of HUTCHMED (HCM), a leading biopharmaceutical company focused on oncology and immunology drugs, soared 7.58% on Thursday after the UK's healthcare regulator granted approval for its drug Fruquintinib to treat metastatic colorectal cancer in adult patients.</p>\n\n<p>The Medicines and Healthcare products Regulatory Agency (MHRA) approval marks a significant milestone for HUTCHMED, allowing the company to market Fruquintinib in the UK for colorectal cancer treatment. Fruquintinib is a highly selective and potent oral inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3.</p>\n\n<p>The regulatory greenlight bolsters HUTCHMED's oncology portfolio and is expected to drive revenue growth for the company. Analysts view the approval as a positive development, highlighting the drug's potential in addressing a significant unmet medical need in the treatment of metastatic colorectal cancer.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00013","symbol_name":"和黄医药","start_time":0,"source_url":"","article_id":"1151558670","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1151558670","pubTimestamp":1726835540,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of HUTCHMED , a leading biopharmaceutical company focused on oncology and immunology drugs, soared 7.58% on Thursday after the UK's healthcare regulator granted approval for its drug Fruquintinib to treat metastatic colorectal cancer in adult patients.The Medicines and Healthcare products Regulatory Agency  approval marks a significant milestone for HUTCHMED, allowing the company to market Fruquintinib in the UK for colorectal cancer treatment. Fruquintinib is a highly selective and poten","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"00013":"和黄医药"},"translate_title":"英国批准抗癌药物呋喹替尼，和黄医药股价飙升","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00013":1},"content_text":"Shares of HUTCHMED (HCM), a leading biopharmaceutical company focused on oncology and immunology drugs, soared 7.58% on Thursday after the UK's healthcare regulator granted approval for its drug Fruquintinib to treat metastatic colorectal cancer in adult patients.\nThe Medicines and Healthcare products Regulatory Agency (MHRA) approval marks a significant milestone for HUTCHMED, allowing the company to market Fruquintinib in the UK for colorectal cancer treatment. Fruquintinib is a highly selective and potent oral inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3.\nThe regulatory greenlight bolsters HUTCHMED's oncology portfolio and is expected to drive revenue growth for the company. Analysts view the approval as a positive development, highlighting the drug's potential in addressing a significant unmet medical need in the treatment of metastatic colorectal cancer.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}